Tags: blood | thinner | brilinta | astrazeneca

New Blood Thinner Shown to Cut Heart Attack Risk

Wednesday, 14 January 2015 08:09 AM EST

AstraZeneca's blood-thinning drug Brilinta cut the risk of death or heart attack in patients with a history of previous attacks, according to a major clinical trial that will boost hopes for the closely watched product.
 
Giving Brilinta to patients who had a heart attack over a year ago could more than double the number of people eligible for the medicine, which the company has predicted could eventually generate sales of $3.5 billion a year.

Results from the 21,000-patient study, known as PEGASUS, were released on Wednesday, lifting shares in AstraZeneca 1.5 percent.
 
The trial, which studied subjects who had a heart attack within the past one to three years, was designed to prove Brilinta's value beyond its current approved use in patients with acute coronary syndromes, or recent attacks.

Brilinta has struggled so far to gain traction in a competitive market for blood thinners, where Plavix -- developed by Sanofi and Bristol-Myers Squibb -- is now available as a cheap generic. Brilinta also competes with Eli Lilly's Effient.

AstraZeneca Chief Executive Pascal Soriot has made Brilinta a top priority and the company flagged its potential when he fought off a $118 billion bid by Pfizer last year, forecasting annual sales of $3.5 billion for the drug by 2023.

Tom Keith-Roach, vice president for Brilinta, told Reuters he expected sales to strengthen through 2015 and the latest positive trial results should lead to expanded approvals in major markets over the next 18 months.

"This is very important news for the franchise," he said.

Analysts agreed the study was a clear win for AstraZeneca but said they wanted to see full details on the magnitude of clinical benefit, as well as data on bleeding. All blood-thinning drugs can cause bleeds.

So far, AstraZeneca has only said that the PEGASUS data was positive for both the 60 mg and 90 mg doses of Brilinta, when given alongside low-dose aspirin, and that preliminary analysis did not reveal any unexpected safety issues.

Complete results from the study will be submitted to a scientific meeting in 2015.

AstraZeneca is also conducting further studies looking at Brilinta's use in stroke, peripheral artery disease and diabetes.

© 2025 Thomson/Reuters. All rights reserved.


Health-News
AstraZeneca's blood-thinning drug Brilinta cut the risk of death or heart attack in patients with a history of previous attacks, according to a major clinical trial that will boost hopes for the closely watched product. Giving Brilinta to patients who had a heart attack over a...
blood, thinner, brilinta, astrazeneca
358
2015-09-14
Wednesday, 14 January 2015 08:09 AM
Newsmax Media, Inc.

Sign up for Newsmax’s Daily Newsletter

Receive breaking news and original analysis - sent right to your inbox.

(Optional for Local News)
Privacy: We never share your email address.
Join the Newsmax Community
Read and Post Comments
Please review Community Guidelines before posting a comment.
 
Find Your Condition
Newsmax2 Live
 
On Now:12:00p ET • John Bachman Now
Coming Up:2:00p ET • National Desk
Get Newsmax Text Alerts

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© 2025 Newsmax Media, Inc.
All Rights Reserved
NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved